Navigating GLP-1 and GIP Agonists: What is the Equivalent Dose of Mounjaro to Ozempic?

Last reviewed: June 10, 2026

Last updated: June 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Mounjaro (tirzepatide) and Ozempic (semaglutide) are both GLP-1 receptor agonists, but tirzepatide adds a second mechanism—GIP receptor activation—that changes how doses compare. Understanding this difference is essential when choosing between these medications for weight loss. PlexusDx offers both medications as compounded formulations, allowing patients to access personalized therapy without insurance barriers.

Why Mounjaro and Ozempic Doses Cannot Be Directly Compared

Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist. Ozempic contains semaglutide, which activates only the GLP-1 receptor. Because tirzepatide engages two separate weight-loss pathways simultaneously, a lower tirzepatide dose may produce effects similar to a higher semaglutide dose. Directly converting one medication's dose to the other ignores this pharmacological difference and can lead to under- or over-treatment.

Clinical trials did not design tirzepatide and semaglutide to share equivalent dosing schedules. Tirzepatide dosing starts at 2.5 mg weekly, while semaglutide begins at 0.25 mg weekly. These starting points reflect each drug's potency profile, not arbitrary choice. The GIP pathway adds metabolic benefits beyond appetite suppression, including improved insulin secretion and hepatic glucose control.

GIP Receptor Activation: The Extra Mechanism Behind Tirzepatide

Glucose-dependent insulinotropic polypeptide (GIP) receptors regulate blood sugar levels, energy expenditure, and fat tissue metabolism independently of GLP-1 activity. When tirzepatide binds to GIP receptors, it triggers insulin release only when blood glucose is elevated, reducing hypoglycemia risk. This dual-pathway approach explains why tirzepatide achieved greater weight loss in head-to-head trials compared to semaglutide at equivalent timepoints.

The GIP mechanism may explain why some patients respond better to tirzepatide than semaglutide, even at lower nominal doses. Real-world outcomes suggest tirzepatide produces more rapid initial weight loss and sustained metabolic improvement. However, individual genetic variation in GIP1R expression means response intensity differs between patients—a reason why PlexusDx offers Precision Peptide Genetic Testing to identify optimal candidate pathways.

Clinical Trial Evidence: Weight Loss Outcomes Across Dose Ranges

In the SURPASS-1 trial, tirzepatide 15 mg weekly produced an average 22.5% body weight reduction over 52 weeks. By comparison, in the SUSTAIN-7 trial, semaglutide 1 mg weekly (the highest approved dose) achieved approximately 17.5% weight loss. These results demonstrate that tirzepatide's dual mechanism typically outperforms semaglutide, even when tirzepatide doses are numerically lower. Patients switching between medications should not assume a simple mathematical conversion applies.

Weight loss plateaus and individual variation mean some patients require higher final doses of either agent. Tirzepatide doses escalate to 10 mg, 12.5 mg, and 15 mg weekly as tolerance builds. Semaglutide escalates to 0.5 mg, 1 mg, and higher. PlexusDx dosing flexibility allows providers to adjust therapy based on patient response and tolerability, with a flat monthly price that never changes as dose increases—keeping affordability constant regardless of titration needs.

Choosing Between Tirzepatide and Semaglutide: A Personalized Decision

The choice between tirzepatide and semaglutide depends on individual metabolic profile, insulin sensitivity, tolerance for side effects, and genetic predispositions. Patients with elevated fasting glucose, prediabetes, or insulin resistance may benefit more from tirzepatide's dual GIP-GLP-1 action. Those with isolated appetite control needs or who experience GIP-related GI side effects might respond better to semaglutide monotherapy.

PlexusDx Precision Peptide Genetic Test identifies variants in GIPR (rs1800437) and FTO (rs9939609), and MC4R (rs17782313) that influence individual response to these medications. Testing costs only $298. This genetic insight removes guesswork and enables truly personalized therapy selection, helping you avoid ineffective medications and optimize your weight loss protocol from the start.

PlexusDx Tirzepatide Compounded Injections: Access and Affordability

PlexusDx offers compounded tirzepatide injections from licensed 503A pharmacies at a flat rate of $289 per month, regardless of your current dose. Whether you start at 2.5 mg or titrate to 15 mg weekly, your monthly cost remains the same—eliminating the financial penalty of dose escalation that patients face with brand medications. PlexusDx serves all 50 states, requires no insurance, and accepts HSA and FSA funds for additional savings.

Compounded formulations maintain bioequivalence to brand medications while removing distribution markups and pharmacy benefit manager restrictions. PlexusDx pharmacies are licensed 503A facilities, ensuring pharmaceutical-grade quality and sterile manufacturing standards. You can start tirzepatide therapy in days, not months, and adjust your protocol as needed without cost surprises or insurance authorization delays.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is 5 mg of Mounjaro equivalent to 0.5 mg of Ozempic?

No direct equivalency exists because tirzepatide engages both GLP-1 and GIP pathways, while semaglutide only activates GLP-1 receptors. A lower tirzepatide dose may produce comparable weight loss to a higher semaglutide dose due to the added GIP mechanism. Your response depends on individual genetics, metabolism, and baseline health status—reasons PlexusDx recommends genetic testing for personalized dosing guidance.

Does tirzepatide work faster than semaglutide for weight loss?

Clinical trials show tirzepatide typically produces more rapid initial weight loss compared to semaglutide at matched timepoints. By 16 weeks, tirzepatide users often report greater appetite suppression and metabolic shift. However, individual variation is significant—some patients respond equally well or better to semaglutide. PlexusDx Precision Peptide Genetic Testing identifies which pathway activation pattern matches your genetic predisposition for optimal outcomes.

Can I switch from Ozempic to Mounjaro without dose conversion issues?

Yes, but the transition should be guided by a healthcare provider, not by direct dose matching. Most patients switching to tirzepatide start at the standard 2.5 mg weekly dose, regardless of their prior semaglutide dose. Your provider will monitor tolerability and adjust based on your response. PlexusDx patients can switch medications with full pricing transparency—your $289/month tirzepatide cost remains flat across all dose levels.

What are the main side effects of tirzepatide compared to semaglutide?

Both medications commonly cause nausea, vomiting, and diarrhea during dose escalation, though tirzepatide's GIP pathway may increase gastrointestinal effects in some patients. Hypoglycemia risk is low with either drug when used for weight loss alone (not diabetes treatment). Pancreatitis and gallbladder issues are rare but possible with all GLP-1 agonists. Report persistent symptoms to your provider—PlexusDx supports dose adjustments or medication switches to optimize your tolerability.

How does the Precision Peptide Genetic Test improve my medication choice?

No — the Precision Peptide Genetic Test does not predict your response to Mounjaro or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Mounjaro Vs Glp 1
• Glp 1 Vs Mounjaro
• Glp 1 Starting Dose
• Glp 1 Mounjaro

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.